financetom
Business
financetom
/
Business
/
US, Canadian pot firms eye Germany for growth as market stagnates at home
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US, Canadian pot firms eye Germany for growth as market stagnates at home
Jul 23, 2024 7:09 AM

By Sourasis Bose

(Reuters) - North American cannabis firms, facing prohibitive laws, an overcrowded market and a deeply entrenched illicit sector at home are ramping up investments in Germany after the country partly legalized marijuana use.

Germany, the largest medical cannabis market in Europe, decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe it.

But only a few local companies are licensed to grow pot, and U.S. and Canadian firms are looking to capture a slice of the market by providing capital and exporting products to Germany.

Industry insiders said this is mostly driven by problems at home, with Canada plagued by an illicit market and oversupply. In the U.S., allure has dimmed amid regulatory hurdles, including a lack of timeline for federal legalization.

"Canadian market is very challenging for these producers and Germany is probably the largest opportunity for them," said Frederico Gomes, analyst at brokerage ATB Capital Markets.

Two German companies, including its largest cannabis producer Demecan and online seller Bloomwell Group, told Reuters they are in talks with US and Canadian companies for potential investments, and more deals may be announced in the coming days.

"We see a big movement in the global market. Everybody needs to be in Germany and wants to be in Germany now," said Bloomwell CEO Niklas Kouparanis.

Canada's OrganiGram ( OGI ) had in June announced a 14 million euro ($15.21 million) investment - 16.5% of its overseas investments funds - in Berlin-based Sanity Group.

A demand spike following decriminalization would further encourage investors, with Cannabis research firm BDSA estimating Germany's marijuana sales to hit $1.5 billion in 2024 and $3.7 billion by 2027.

Bloomwell said it added more patients in the three months following reclassification, compared to its first four years in business.

Another draw is that Germany does not impose high taxes on medical marijuana sales, keeping prices competitive to the illicit market in contrast to Canada, OrganiGram ( OGI ) CEO Beena Goldenberg said.

($1 = 0.9202 euros)

(Reporting by Sourasis Bose in Bengaluru; Editing by Arpan Varghese and Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Baker Hughes Reports Over $100 Million Tariff Impact as Expected
Market Chatter: Baker Hughes Reports Over $100 Million Tariff Impact as Expected
Oct 13, 2025
12:29 PM EDT, 10/13/2025 (MT Newswires) -- Baker Hughes ( BKR ) has seen a tariff impact of over $100 million this year, in line with its guidance provided in April, Bloomberg reported Monday, citing Chief Executive Officer Lorenzo Simonelli. It is an incremental pressure point, but it's something we have to manage through, Bloomberg quoted Simonelli as saying at...
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
Oct 13, 2025
ENDRA Life Sciences Inc. ( NDRA ) shares jumped after the company announced $4.9 million in funding commitments from institutional and cryptocurrency investors to launch a new digital asset treasury strategy. The initiative will focus on high-conviction decentralized finance holdings managed by Arca Investment Management LLC. The private placement includes 744,340 shares of common stock, as well as prefunded warrants...
MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says
MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says
Oct 13, 2025
12:29 PM EDT, 10/13/2025 (MT Newswires) -- MannKind's ( MNKD ) supplemental biologics license application for Afrezza to treat children and adolescents with type 1 or type 2 diabetes is facing limited regulatory risk as the company aims for an approval that would expand the drug's addressable market by another 300,000 patients, Wedbush said in a Monday note. Wedbush said...
Power Integrations Collaborates With Nvidia on 800 VDC AI Data Centers
Power Integrations Collaborates With Nvidia on 800 VDC AI Data Centers
Oct 13, 2025
11:48 AM EDT, 10/13/2025 (MT Newswires) -- Power Integrations ( POWI ) said Monday it is collaborating with Nvidia ( NVDA ) to accelerate the transition to 800 VDC power architecture and megawatt-scale racks for artificial intelligence data centers. The company's 1250 V and 1700 V PowiGaN devices are designed to match the rising power density requirements in 800 VDC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved